“It was also somewhat surprising to see that the use of IBD medications had only limited impact on the risk,” Dr. Loftus noted. “A more detailed breakdown of ‘current’ versus ‘previous’ use of these medications may have been able to sort this out better.”
Related Articles
Case Report: Possible Overlapping Vasculitis & Ulcerative Colitis
A 42-year-old man with a history of ulcerative colitis (UC), primary sclerosing cholangitis (PSC) and chronic sinusitis was referred to a rheumatologist to evaluate for a possible diagnosis of systemic vasculitis. This patient had developed new skin lesions, gingival hypertrophy and ulcerating tracheobronchitis, concerning for possible granulomatosis with polyangiitis (GPA). Since 1994, the patient had…
Gut Feeling: A Comprehensive Look at the Pathogenesis, Management & Treatment of Inflammatory Bowel Disease
Patients with autoimmune diseases, such as spondyloarthritis, are at risk of developing inflammatory bowel disease. Here are considerations for its management and treatment.
Volatility of the Gut Microbiome Tied to IBD
NEW YORK (Reuters Health)—Fluctuations in the gut microbiome over time could underlie inflammatory bowel disease (IBD), including Crohn’s and ulcerative colitis, researchers suggest. “Both the state and the dynamics of the human gut microbiome in healthy individuals are highly personalized. Although cross-sectional studies have revealed dysbiosis of the gut microbiome in IBD, little is known…
Rheumatology Practices Need Sharp Focus on Patient Care Safety, Quality
“It is not necessary to change. Survival is not mandatory.” —W. Edwards Deming For practices to survive, change is a requirement—not an option—in the rapidly evolving practice of rheumatology care. ad goes here:advert-1ADVERTISEMENTSCROLL TO CONTINUEPharmaceutical therapies are advancing quickly, opening the door for game-changing therapies in the treatment of chronic autoimmune disorders. With these advances…